Division of Cardiovascular Diseases, Department of Internal Medicine, Rochester, Minnesota; Department of Health Sciences Research, Rochester, Minnesota.
Division of Cardiac Surgery, University Hospitals in Cleveland Ohio.
J Heart Lung Transplant. 2014 Apr;33(4):359-65. doi: 10.1016/j.healun.2013.12.014. Epub 2013 Dec 27.
Frailty is recognized as a major prognostic indicator in heart failure. There has been interest in understanding whether pre-operative frailty is associated with worse outcomes after implantation of a left ventricular assist device (LVAD) as destination therapy.
Patients undergoing LVAD implantation as destination therapy at the Mayo Clinic, Rochester, Minnesota, from February 2007 to June 2012, were included in this study. Frailty was assessed using the deficit index (31 impairments, disabilities and comorbidities) and defined as the proportion of deficits present. We divided patients based on tertiles of the deficit index (>0.32 = frail, 0.23 to 0.32 = intermediate frail, <0.23 = not frail). Cox proportional hazard regression models were used to examine the association between frailty and death. Patients were censored at death or last follow-up through October 2013.
Among 99 patients (mean age 65 years, 18% female, 55% with ischemic heart failure), the deficit index ranged from 0.10 to 0.65 (mean 0.29). After a mean follow-up of 1.9 ± 1.6 years, 79% of the patients had been rehospitalized (range 0 to 17 hospitalizations, median 1 per person) and 45% had died. Compared with those who were not frail, patients who were intermediate frail (adjusted HR 1.70, 95% CI 0.71 to 4.31) and frail (HR 3.08, 95% CI 1.40 to 7.48) were at increased risk for death (p for trend = 0.004). The mean (SD) number of days alive out of hospital the first year after LVAD was 293 (107) for not frail, 266 (134) for intermediate frail and 250 (132) for frail patients.
Frailty before destination LVAD implantation is associated with increased risk of death and may represent a significant patient selection consideration.
衰弱被认为是心力衰竭的主要预后指标。人们一直有兴趣了解术前衰弱是否与左心室辅助装置(LVAD)作为终末期心衰治疗后植入的预后较差有关。
本研究纳入 2007 年 2 月至 2012 年 6 月在明尼苏达州罗切斯特市梅奥诊所接受 LVAD 作为终末期心衰治疗的患者。使用缺陷指数(31 项损伤、残疾和合并症)评估衰弱,并定义为存在缺陷的比例。我们根据缺陷指数的三分位数(>0.32=衰弱,0.23 至 0.32=中度衰弱,<0.23=不衰弱)将患者分为三组。使用 Cox 比例风险回归模型来检查衰弱与死亡之间的关系。患者在死亡或 2013 年 10 月最后一次随访时被删失。
在 99 例患者(平均年龄 65 岁,18%为女性,55%为缺血性心力衰竭)中,缺陷指数范围为 0.10 至 0.65(平均 0.29)。平均随访 1.9±1.6 年后,79%的患者再次住院(范围 0 至 17 次住院,中位数为每人 1 次),45%的患者死亡。与非衰弱患者相比,中度衰弱(调整后的 HR 1.70,95%CI 0.71 至 4.31)和衰弱(HR 3.08,95%CI 1.40 至 7.48)患者死亡风险增加(趋势检验 p=0.004)。LVAD 植入后第一年,非衰弱患者的院外存活天数的平均值(标准差)为 293(107)天,中度衰弱患者为 266(134)天,衰弱患者为 250(132)天。
LVAD 植入前的衰弱与死亡风险增加相关,可能代表着重要的患者选择考虑因素。